Boost For European Biotech As €345m Fund Opens
Executive Summary
Edmond De Rothschild Investment Partners unveils the largest life science and medical device venture fund to be raised in Europe. Olivier Litzka tells Scrip that the continent can now boast a public market machinery that contributes to potentially lucrative exits for investors.
You may also be interested in...
Allergan Up For Alzheimer's Challenge With Chase Buy
Allergan is paying $125m for Chase Pharmaceuticals and its Alzheimer's disease candidate CPC-201 that has completed Phase II testing. The modest upfront reflects the Phase III graveyard that Alzheimer's disease represents. Chase is led by two former Allergan executives.
Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn
Allergan will pay a huge premium – up to $1.7bn in a milestone-heavy deal – for Tobira and $50m up front for the preclinical startup Akarna to expand its gastrointestinal franchise into the potentially lucrative NASH market.
Pierre Fabre Continues Oncology R&D Push
The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.